• Thu news: Industry M&A volume down 8% over 2023. Pfizer’s Ibrance improves breast cancer survival. Lonza shedding capsule biz. AZ’s Lynparza in early breast cancer. Trump wants childhood vaccine discussion. See more on our front page

$3 per share













$3/share - those were the days. Gotta love SEC filings with language like

"Management does not believe that the current available cash and cash equivalents will be sufficient to fund the Company’s planned expenditures and meet its obligations for at least 12 months following the financial statement issuance date without raising additional funding. As a result, there is substantial doubt about the Company’s ability to continue as a going concern for 12 months following the issuance date of the condensed consolidated financial statements for the three months ended March 31, 2021."